Article
05 Dec 2025
The Federal Redefinition Of Hemp: Impacts, Uncertainty, And Next Steps For Businesses
RANKINGS
This author falls within the Top 20% for their listed topics and industry categories. Based on Mondaq users readership, this author is ranked as VERY POPULAR in United States
AUTHORS CONTENT
Article
27 Oct 2025
California's AB 1264 Introduces The First Legal Definition Of Ultra-Processed Food
Article
16 Sep 2025
FDA On The Offense! Targeting Pharmaceutical Company Drug Advertising In Wave Of Enforcement Actions
Article
11 Aug 2025
GLP-1 Drugs: Ohio Board Of Pharmacy Issues FAQs For Compounders
Article
17 Jul 2025
FDA: Commissioner's National Priority Voucher Program Aims To Streamline Some Drug Reviews
Article
25 Jun 2025
Direct-To-Consumer Drug Ads Are Under Attack – Pharmaceutical Companies Beware
Article
09 Jun 2025
GLP-1 Compounded Medications Targeted By Connecticut Attorney General
Article
20 May 2025
"AI Policy Roadmap" Released By AdvaMed To Guide Regulators
Article
24 Apr 2025
MedTech Round Table: What The Trump Administration Means For Companies And Investors
Article
05 Apr 2025
Texas Court Vacates FDA's Laboratory Developed Test (LDT) Final Rule
Article
27 Mar 2025
DEA Buprenorphine Rule Delayed To December 31, 2025
Article
19 Mar 2025
Compounded GLP-1 Drugs: Texas Judge Denies PI Motion And Request For Stay Of FDA's Declaration That Tirzepatide Shortage Is Resolved; Plaintiff OFA Appeals
Article
26 Feb 2025
Make Food "Healthy" Again: FDA's Resolution For A Healthier 2025
Article
27 Jan 2025
DEA Unveils Long-Overdue Special Registration For Telemedicine In Proposed Rule
Article
10 Jan 2025
Scientific Information On Unapproved Uses Of Medical Products: FDA's Final Guidance On Firm Communication To Health Care Providers
Article
09 Jan 2025
AI-Enabled Device Software Functions: FDA's Final Guidance For Predetermined Change Control Plans
Article
02 Jan 2025
GLP-1 Drugs: FDA "Re-Confirms" Decision Removing Tirzepatide From The Drug Shortage List
Article
27 Dec 2024
FDA Targets GLP-1 Providers With Warning Letters
Article
03 Dec 2024
GLP-1 Drugs: Brand Companies Push FDA To Limit Compounding
Article
09 Oct 2024
GLP-1 Drugs: FDA Removes Lilly's Zepbound® And Mounjaro® (Tirzepatide Injection) From Its Drug Shortage List
